Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12
Capricor Therapeutics, a biotech firm specializing in cell and exosome-based therapies for rare diseases, will release its Q1 2026 financial results on May 12, 2026, followed by a conference call and webcast. The company highlighted its lead candidate, Deramiocel, targeting Duchenne muscular dystrophy, and discussed its proprietary StealthX platfor…